81 results about "Adiponectin" patented technology

To provide an adiponectin enhancer and an oral composition for enhancing adiponectin, having the effect of enhancing adiponectin.SOLUTION: An adiponectin enhancer comprises plasmalogen as an active ingredient.SELECTED DRAWING: Figure 1

The invention discloses a rice sheath blight resistant adiponectin receptor OsPLS3 protein as well as an encoding protein and application thereof. The amino acid sequence of the rice adiponectin receptor OsPLS3 protein is as shown in SEQ ID NO. 3. The genome nucleotide sequence of the encoding gene of the rice adiponectin receptor gene OsPLS3 is as shown in SEQ ID NO.1, and the nucleotide sequence of the open reading frame of the rice adiponectin receptor gene OsPLS3 is as shown in SEQ ID NO.2. The invention further discloses a preparation method of the rice adiponectin receptor gene OsPLS3. Experiments prove that after the rice adiponectin receptor gene OsPLS3 is over-expressed in rice, the resistance of the rice to sheath blight can be improved, and after the rice adiponectin receptor gene OsPLS3 is knocked out, the rice adiponectin receptor gene OsPLS3 is more susceptible to rhizoctonia solani, namely, the resistance of the rice to the sheath blight is positively regulated by the OsPLS3. The rice adiponectin receptor gene OsPLS3 provided by the invention has an important production value for rice sheath blight resistance breeding.

The invention relates to the technical field of a preparation method of a determination kit for in-vitro determination of adiponectin in a human body, and particularly discloses a preparation method of a determination kit for in-vitro determination of adiponectin in a human body, which comprises the following steps: a coupling process; an S-shaped bent pipe is installed on the side connector, an upper connector is kept in an open state, a perfusion device adds 0.3-0.4 volume of a sealing buffer solution into the glass bottle, and 0.1-0.2 volume of the sealing buffer solution is injected into the glass bottle through an injection connector; and a storage process: closing the filling interface, opening the cover body, installing the up-down extending pipe, covering the cover body, opening the filling interface, carrying out resuspension ultrasonic treatment by using the storage buffer solution, and carrying out centrifugal washing for three times, thereby finally obtaining the adiponectin latex antibody. The device is easy and convenient to operate, simple in structure, independent of the manual control level and high in preparation efficiency, the situation that materials are left in a small-size glass bottle, consequently, the material ratio is difficult to control, and a small amount of confining liquid is needed is avoided, and the prepared adiponectin latex antibody is good in accuracy.

The present invention discloses an adiponectin detection kit and a preparation method thereof, wherein the adiponectin detection kit comprises an R1 reagent and an R2 reagent; the R1 reagent comprises the following components: a buffer solution, an electrolyte, a fusogen, a surfactant and a preservative; the R2 reagent comprises the following components: anti-adiponectin monoclonal antibody coated latex particles, a buffer solution, a protective agent, a stabilizer, a preservative and a surfactant; wherein the surfactant is selected from one or two of Tetronic 1307 and castor oil polyoxyethylene ether. The kit of the present invention not only enhances the anti-interference ability of the reagent to special samples such as chyle and lipid turbidity samples, reduces the interference of nonspecific adsorption, improves the accuracy of sample testing, but also enhances the repeatability and stability of the latex reagent by adopting a new surfactant combination in combination with other components in the kit.

Compositions and methods diagnose and / or treat chronic kidney disease (CKD) using one or more feline circulating proteins as markers for early-stage CKD. A method of diagnosing chronic kidney disease (CKD) in a feline can include measuring an amount of each of at least one circulating protein from the feline. The at least one circulating protein is one or more of adiponectin (ADIPOQ), cathelicidin (CAMP), kinesin-like protein (KIF12), plasma retinol-binding protein (RBP4), Ig-like domain-containing protein (ZKSCAN1), coagulation factor X (F10), fibronectin (FN1) and mixtures thereof. The method also includes performing comparison of the amount of each of the at least one circulating protein from the feline to a corresponding predetermined value or a corresponding predetermined range. The method also includes diagnosing the feline as having early-stage CKD or not having early-stage CKD, based on the comparison.

The invention discloses a composition with effects of losing weight and reducing blood fat. Every 100g of the composition comprises the following components and contents: (1) 10-30mg of adiponectin functional fragments; (2) 5 to 15 mg of PCSK9 inhibitory peptide; (3) 1-5 g of a radix puerariae extract; (4) 1-3 g of garcinia cambogia extract; (5) 0.5-2 g of a green coffee bean extract; (6) 1 to 3g of microencapsulated fish oil; (7) 0.5 to 1g of chitosan; and 5 to 10 g of erythritol. Through the synergistic effect of various bioactive components, the composition can effectively reduce fat accumulation and reduce the blood fat level, and meanwhile has good taste and use convenience. The composition disclosed by the invention provides an innovative solution for losing weight and reducing blood fat, and has potential clinical and commercial application values.

The invention discloses a juvenile depressive disorder diagnosis marker, a depressive disorder diagnosis model and application thereof, and relates to the technical field of mental disorder diagnosis. Adiponectin is applied to auxiliary diagnosis or diagnosis of adolescent depressive disorder, the AUC value of a diagnosis model is larger than 0.7, and the adiponectin is high in diagnosis sensitivity and specificity and can serve as a diagnosis or auxiliary diagnosis marker of adolescent depressive disorder. Adiponectin and other indexes are combined for detection, the diagnosis performance of auxiliary diagnosis of juvenile depressive disorder can be improved, and the method has a good clinical application prospect.

This invention discloses a method and sensor for adiponectin detection using a polyaniline and polyacrylic acid-modified wire mesh carbon electrode, relating to the field of adiponectin detection technology. The method involves electrochemically activating the wire mesh carbon electrode, electropolymerizing it to form a polyaniline-polyacrylic acid composite modification layer, immobilizing adiponectin monoclonal antibody after activation with N-hydroxysuccinimide and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, blocking the antibody with bovine serum albumin, and reacting it with a serum sample. The adiponectin concentration is determined based on the peak potential shift and peak current change. This invention simultaneously achieves both conductive transport and antibody immobilization, reduces non-specific adsorption and serum interference, and improves detection sensitivity, repeatability, and quantitative accuracy.

The application discloses a construction method of a fat-targeted gene therapy vector. The method comprises the following steps: obtaining a fat tissue-specific promoter sequence; obtaining a shRNA coding sequence targeting a Tks4 gene; cloning the promoter sequence and the shRNA coding sequence into an adeno-associated virus vector skeleton to construct a recombinant expression vector; and co-transfecting the recombinant expression vector and an auxiliary plasmid into a packaging cell to package and purify a recombinant adeno-associated virus particle. The vector constructed by the application adopts an adiponectin promoter to drive the expression of miR30-shRNA targeting the Tks4, and can be specifically expressed in fat tissues and livers after being injected through a tail vein, significantly inhibits fat cell hypertrophy and systemic fat accumulation induced by a high-fat diet, reduces the serum cholesterol level, does not cause an immune inflammatory reaction, does not affect sugar metabolism, and is not expressed in non-target tissues. The application provides a safe and efficient new strategy for the gene therapy of obesity, hyperlipidemia, fatty liver and related metabolic diseases.

The invention belongs to the technical field of electrochemical analysis and detection, and particularly relates to an electrochemical immunosensor for detecting adiponectin as well as a preparation method and application of the electrochemical immunosensor. The preparation method comprises the following steps: (1) connecting a screen-printed electrode SPCE to an electrochemical workstation by using a 0.01 M PBS (Phosphate Buffer Solution) with the pH value of 7.4, performing-0.2 V-1. 2V cyclic voltammetry scanning, and activating for 10 circles under 50mV / S; and (2) by taking 0.01-1M H2SO4 as a base solution, connecting the screen-printed electrode SPCE to an electrochemical workstation, carrying out electro-polymerization on poly-o-phenylenediamine in a 50-100mM o-phenylenediamine and NH2-UiO-66 solution to form a poly-o-phenylenediamine and NH2-UiO-66 composite modified electrode, washing with deionized water, and drying at room temperature. (3) soaking the modified electrode in a glutaraldehyde solution for 10-70 minutes, cleaning with deionized water, drying at room temperature, adding 10-100 [mu] L of ADPN antibody solution and 100-600 [mu] g / mL of ADPN antibody solution, and incubating; and (4) washing with ionized water, drying at room temperature, preventing non-specific binding sites at 37 DEG C for 0.5-1.5 hours by using 3-10 microliters of 0.8-1.2 wt% casein solution, and washing the screen-printed electrode again to obtain the electrochemical immunosensor.

The invention discloses a preparation method of an electrochemical immunosensor for detecting adiponectin and a method for quantitatively detecting the adiponectin by adopting the electrochemical immunosensor, provides a new strategy for fixing an adiponectin antibody by a one-step method, and constructs the electrochemical immunosensor based on a gold sputtering silver wire screen printing electrode (Au / AgSPE). The rapid, high-sensitivity and stable detection of the adiponectin is realized, so that the conversion of the adiponectin detection technology to instant detection application is promoted. Only a portable electrochemical workstation is needed in the detection process, and large biochemical analysis equipment is not needed. And the screen printing electrode and the sputtering technology support large-scale production, and cost reduction and popularization are facilitated.

The present invention includes methods of using improved compositions and improved compositions comprising thermally stable plant juice soluble vegetable proteins for resisting pathogenic effects; the improvements include that the composition comprising heat stable plant juice soluble vegetable proteins is essentially a water insoluble concentrated substance free of components that are more soluble in plant juice, and is enriched in heat stable proteins of plant juice; dosage forms prepared from the composition are useful for adiponectin agonist action for reducing the risk of one or more conditions selected from the group consisting of type II diabetes, hyperlipidemia, atherosclerosis, hypertension, heart disease and obesity, and are useful for antimicrobial action for reducing the risk of one or more conditions selected from the group consisting of type II diabetes, hyperlipidemia, atherosclerosis, hypertension, heart disease and obesity. The present invention relates to antimicrobial agents for reducing the risk of or treating microbial infections in plants and animals with or without synergy with other antimicrobial agents. The present invention includes a composition substantially characterized by the infrared absorption spectrum provided in the present invention.

The present invention discloses a preparation method and application of a soluble B lymphocyte stimulator receptor 3 and adiponectin globular domain fusion protein. The present invention belongs to the field of biomedical technology. The preparation method includes the following steps: cloning the coding sequences of the extracellular region of BAFF-R3 and the adiponectin globular domain; connecting the extracellular region of BAFF-R3 and the adiponectin globular domain through a peptide chain, and inserting the expression sequence of the eBR3-gAD fusion protein into a plasmid using restriction enzymes and DNA ligase; transfecting the above plasmid into cells and screening out a cell line with stable expression; culturing the above cell line, collecting the supernatant, and purifying by gel filtration and chromatography to obtain the soluble B lymphocyte stimulator receptor 3 and adiponectin globular domain fusion protein. The preparation method of this novel fusion protein has the advantages of high specificity, high expression level, and simple purification.

The application discloses a rice anti-Rhizoctonia solani leptin receptor OsPLS3 protein and an encoding protein and application thereof. The rice leptin receptor OsPLS3 protein has an amino acid sequence as shown in SEQ ID NO. 3. A coding gene of the rice leptin receptor gene OsPLS3 has a genomic nucleotide sequence as shown in SEQ ID NO. 1, and an open reading frame nucleotide sequence of the rice leptin receptor gene OsPLS3 is as shown in SEQ ID NO. 2. Experiments prove that overexpression of the rice leptin receptor gene OsPLS3 in the application in rice can improve the resistance of the rice to the Rhizoctonia solani, and the rice is more susceptible to the Rhizoctonia solani after knockout, namely, the OsPLS3 positively regulates the resistance of the rice to the Rhizoctonia solani. The rice leptin receptor gene OsPLS3 has important production value for breeding of the rice resistant to the Rhizoctonia solani.

A biological function regulating agent comprises a fermented collagen peptide, and the fermented collagen peptide has at least one action selected from the group consisting of an epidermal metabolism promoting action, a fat accumulation inhibiting action, a fat decomposition promoting action and an action of regulating the amount of adipocytokine in a biological body.

Disclosed are compositions and methods for the use of adiponectin peptidomimetics in therapeutic applications. The compositions can include a peptide, for example, D-Asn-Ile-Pro-Nva-Leu-Tyr-D-Ser-Phe-Ala-D-Ser-NH2, a solubilizer, a surfactant(s), a buffer, optionally boric acid and optionally mannitol. The osmolality of the composition can be between 260 to 330 mOsm / kg and the pH can be between 4.5 to 5.5. Methods of using the compositions in treating certain eye disease(s) are also disclosed.

The invention provides a breast cancer risk assessment method which is suitable for BI-RADS compact type high-risk groups with BMI greater than or equal to 28 and estrogen greater than 50pg / mL, and the method comprises the following steps: S100, injecting a temperature-sensitive nano contrast agent which is matched with fat acoustic impedance at 37 DEG C and has tumor environment impedance mutation at 39-42 DEG C; s200, dynamically adjusting the voltage of the molybdenum target tube according to the BMI and filtering by adopting a 40keV energy spectrum; s300, based on the leptin / adiponectin ratio L, the estrogen E and the focus area A, calculating a risk score according to R = 0.7 L + 0.3 E * (1 + 50A); according to the scheme, through high-risk group limitation, temperature-sensitive contrast enhanced ultrasonic specificity, BMI self-adaptive molybdenum target penetration and a multi-parameter fusion model, the detection precision is remarkably improved, the microfocus detection sensitivity reaches 92.3%, and the specificity reaches 88.7%.

The present invention relates to a novel peptoid derivative, which is a partially modified adiponectin receptor peptide and has higher stability and superior p-AMPK activity than existing adiponectin receptor peptides, and has the advantage of being advantageous for drug formulation due to improved physical properties and activity. Therefore, the peptoid derivative of the present invention can be used for preventing or treating skin inflammatory diseases, wounds, hair loss, fibrosis, metabolic diseases, or cancer, and for preventing or improving aging, sensitive skin, wrinkles, or moisture.

The present application provides a method for producing a Citrus medica L. var. sarcodactylis fermentate with the effect of increasing polyphenol intake and adiponectin content. The method for producing a Citrus medica L. var. sarcodactylis fermentate with the effect of lowering blood lipids comprises the following steps: washing, air-drying, and breaking the cell wall, inoculating and fermenting, comprehensive filtering, sterilizing, and finally forming a Citrus medica L. var. sarcodactylis fermentate that can increase the total polyphenol content in the human body and improve the adiponectin content in the body.

The invention discloses a preparation method of active recombinant human adiponectin hydrogel as well as a product and application thereof. RhAPN (recombinant human adiponectin) gene as shown in SEQ ID NO.2 is connected to a Ser1 promoter to be expressed in silk glands of bombyx mori under regulation and control, transgenic individuals are screened and fed until cocooning, and silk containing recombinant human adiponectin is obtained; the prepared hydrogel can reduce lipid, can effectively treat mouse ulcerative colitis, and can be used for treating colitis.

Systems and methods are provided for providing diabetes patient treatment guidance for a patient in which a biochemical data set is obtained. The biochemical data set comprises test results from a single blood draw of the patient including at least three measurements selected from the set: a high-sensitivity c-reactive protein test, an adiponectin level test, an intact proinsulin level test, an insulin level test, a C-peptide test, a HbA1c test, and an eGFR level test. A demographic data set for the patient is also obtained that comprises the patient's gender and diabetes stage. The biochemical data set and demographic data set is run against one or more rules to determine a first patient therapy pattern. Then, a report is prepared based on an identity of the first therapy patient pattern. The report sets priorities among intervention classes for the patient based on the identity of the first patient pattern.

The present application relates to the technical field of in vitro diagnosis, in particular to a chemiluminescence-based adiponectin detection method, which uses MQ silicon resin-coated Fe3O4 magnetic microspheres as a solid-phase carrier, captures adiponectin in a sample through a double-antibody sandwich immunoreaction, and uses HRP enzyme-labeled detection antibodies to combine with a luminol-phenolic enhanced chemiluminescence system for signal detection. The key lies in significantly reducing non-specific background by optimizing washing conditions and substrate formula, and regulating luminescence kinetics to adapt to the reading window of mainstream chemiluminescence instruments. The present application uses HRP enzyme-catalyzed cascade amplification and an optimized luminol enhancement system, and the detection lower limit is better than that of conventional methods, meeting the needs of early metabolic risk screening for ultra-low concentration detection, the linear detection range covers 0.01 mg / L to 100 mg / L, effectively avoiding the common hook effect in high-concentration samples, and the signal-to-noise ratio is greatly improved, ensuring the reliability of low-value sample detection.

A method for determining the amount of adiponectin in a sample by mass spectrometry includes: (a) subjecting adiponectin from the sample to an ionization source under conditions suitable for generating one or more adiponectin ions detectable by mass spectrometry; (b) determining the amount of one or more adiponectin ions by mass spectrometry; and (c) determining the amount of adiponectin in the sample from the amount of one or more adiponectin ions determined in step (b).

The invention relates to the technical field of adiponectin detection kits, and discloses an immunoturbidimetric kit for detecting ADP, wherein the kit comprises an R1 reagent and an R2 reagent; the R1 reagent comprises: a buffer solution, 10-100 mmol / L; NaCl, 0.1-1 mol / L; an anticoagulant, 10-100 mmol / L; an aggregation promoter, 0.1-1%; a surfactant, 0.1-1 g / L; a preservative, 0.5-1 g / L; and a blocking agent, 0.05-0.2 mg / mL; wherein the anticoagulant in the R1 reagent is EDTA-Na 2 , sodium heparin, sodium citrate or a combination thereof; R2 reagent: buffer and antibody-coated latex microspheres, the preparation process of which requires cross-linking liquid, blocking liquid and preservation liquid; the kit prepared by the present invention achieves the beneficial technical effects of reducing the difference in serum and plasma measurement values, reducing batch differences and improving stability.

The present invention relates to an adiponectin latex immunoturbidimetric assay kit and a preparation method thereof, comprising reagent R1, reagent R2, a calibrator, and a quality control product. Reagent R1 contains an anti-interference agent comprising polyoxyethylene lauryl ether sulfate sodium salt, with a mass content of 0.1%-0.5%; an emulsifier, with a mass content of 0.2%-1%; and triaton, with a mass content of 0.2%-1%. Compared with the prior art, the kit of the present invention has strong anti-interference ability and is applicable to testing blood samples of patients with different physical conditions, particularly capable of accurately measuring special blood samples containing a large number of interfering factors.

Described herein are biological devices and extracts useful for stimulating hair follicles and / or for increasing hair growth. The biological devices include microbial cells transformed with a DNA construct containing genes for producing transforming growth factor β, keratin, adiponectin, and thymosin β4. In some instances, the extracts also include a synthetic pentapeptide, GPIGS. Methods for using the devices and / or extracts to treat the scalp are also provided herein.

Compositions and methods use one or more feline circulating proteins as markers for early chronic kidney disease (CKD) to diagnose and / or treat CKD. A method of diagnosing chronic kidney disease (CKD) in a feline can include measuring an amount of each of at least one circulating protein from the feline. The at least one circulating protein is one or more of adiponectin (ADIPOQ), antibacterial peptide (CAMP), kinetin-like protein (KIF12), plasma retinol binding protein (RBP4), Ig-like domain containing protein (ZKSCAN1), blood coagulation factor X (F10), fibronectin (FN1), and mixtures thereof. The method further comprises comparing the amount of each of the at least one circulating protein from the feline to a respective predetermined value or a respective predetermined range. The method further comprises diagnosing the feline as having or not having early CKD based on the comparison.

The present invention relates to a composition comprising (i) at least one GLP1 receptor (GLP1R) agonist and (ii) at least one engineered extracellular vesicle harboring at least one adiponectin polypeptide exposed at its outer surface. It further relates to the use of said composition as a medicament, and in particular, for treating various diseases.

The present application discloses the use of FGF21 / GLP-1 fusion proteins in the preparation of a medicament for preventing and / or treating at least one of type 2 diabetes, obesity, steatohepatitis, and triglyceridemia. The FGF21 / GLP-1 fusion proteins of the present application are effective in treating at least one of type 2 diabetes, obesity, steatohepatitis, and triglyceridemia, and in particular, can reduce at least one of HbA1c, blood glucose, body weight, liver fat content, ALT, AST, glutamyl transpeptidase, triglyceride, total cholesterol, low-density lipoprotein cholesterol, or increase at least one of adiponectin, insulin sensitivity, and beta-cell function in the subject.

The present invention relates to a novel peptide derivative, which is a partially modified adiponectin receptor peptide and has higher stability and superior p-AMPK activity than existing adiponectin receptor peptides, and has the advantage of being advantageous for drug formulation due to improved physical properties and activity. Therefore, the peptide derivative of the present invention can be used for preventing or treating skin inflammatory diseases, wounds, hair loss, fibrosis, metabolic diseases, or cancer, and for preventing or improving aging, sensitive skin, wrinkles, or moisture.